Asia-Pacific Anticoagulation Therapy Market – Industry Trends and Forecast to 2026

  • Pharmaceutical
  • Published Report
  • Jul 2019
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 224
  • No of Figures: 28

Asia-Pacific Anticoagulation Therapy Market By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific) – Industry Trends and Forecast to 2026

Anticoagulation therapy is a medication used in prevention of blood clots formation and to uphold blood vessels open. Anticoagulants are usually called as blood thinners but in reality it do not thin the blood but only helps to prevent or to reduce blood clot formation/thrombi. There are various anticoagulants available in the market such as vitamin K antagonists, heparin and novel oral anticoagulation which is used for prophylaxis/treatment of various thromboembolic disorders, such as heart attack (myocardial infarction), stroke and deep venous thrombosis (DVT).

Asia-Pacific anticoagulation therapy market is projected to register a substantial CAGR in the forecast period 2019 to 2026.

Segmentation: Asia-Pacific Anticoagulation Therapy Market

Asia-Pacific anticoagulation therapy market is segmented into nine notable segments which are treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel.

  • On the basis of treatment, the market is segmented into deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thromboembolism (AT), stroke and others
  • On the basis of therapeutic class, the market is segmented into novel oral anticoagulation (NOAC), heparin, vitamin k antagonists and others
  • On the basis of drug type, the market is segmented into bivalirudin, dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban, enoxaparin, delteparin and others
  • On the basis of route of administration, the market is segmented into oral and injectable
  • On the basis of therapeutic area, the market is segmented into cardiovascular diseases, oncology, respiratory, nephrology, CNS and others
  • On the basis of procedure, the market is segmented into pre-surgical procedures, post-surgical procedures, kidney dialysis and heart valve replacement
  • On the basis of type, the market is segmented into generics and branded
  • On the basis of end user, the market is segmented into hospitals, clinics, homecare, ambulatory surgical centers and others
  • On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy

Competitive Analysis: Asia-Pacific Anticoagulation Therapy Market

Some of the major players operating in the Asia-Pacific anticoagulation therapy market are Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Aspen Holdings, Shanghai Fosun Pharmaceutical(Group)Co., Ltd., Cipla Inc, Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED, Eagle Pharmaceuticals, Inc., Endo Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corporation, Portola Pharmaceuticals, Inc., Taro Pharmaceutical Industries Ltd., among others.

Recent Developments

  • In November 2018, Daiichi Sankyo Company, Limited launched LIXIANA in Japan. It is a branded version of edoxaban. It is administered to reduce the chance of systemic embolism (SE) and stroke in patients who are having non-valvular atrial fibrillation (NVAF). This product launch will help the company to expand its business in Japan.
  • In June 2018, Mylan N.V. has launched Angiomax’s generic vesion Bivalirudin in 250 mg single-dose vial in injectable form. This product launch will help company to increase its market share in Asia-Pacific anticoagulation therapy.
  • In January 2017, Mitsubishi Tanabe Pharma Corporation has received China Food and Drug Administration (CFDA) approval for Novastan. This approval will help the company to expand its business in China as this approval is given for additional indications acute cerebral infraction.

Research Methodology: Asia-Pacific Anticoagulation Therapy Market

Primary Rependants:

Key Opinion Leaders (KOL’s): Manufacturers, Researchers, Distributors, Bakers and Food Industrialists.

Industry Participants: CEO’s, V.P.’s, Marketing/Product Managers, Market Intelligence Managers and National Sales Managers.


SKU-

TABLE 1 AGEING WORLD POPULATION

TABLE 2 POSTOPERATIVE PULMONARY EMBOLISM OR DEEP VEIN THROMBOSIS IN HIP AND KNEE SURGERIES, 2015

TABLE 3 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 4 ASIA-PACIFIC DEEP VEIN THROMBOSIS (DVT) IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 5 ASIA-PACIFIC PULMONARY EMBOLISM (PE) IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 6 ASIA-PACIFIC ARTERIAL THROMBOEMBOLISM (AT) IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 7 ASIA-PACIFIC STROKE IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 8 ASIA-PACIFIC OTHERS IN ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 9 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 10 ASIA-PACIFIC NOVEL ORAL ANTICOAGUALTANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 11 ASIA-PACIFIC NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 12 ASIA-PACIFIC HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 13 ASIA-PACIFIC HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 14 ASIA-PACIFIC VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 15 ASIA-PACIFIC VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 16 ASIA-PACIFIC OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 17 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 18 ASIA-PACIFIC BIVALIRUDIN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 19 ASIA-PACIFIC DABIGATRAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 20 ASIA-PACIFIC EDOXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 21 ASIA-PACIFIC BETRIXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 22 ASIA-PACIFIC RIVAROXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 23 ASIA-PACIFIC APIXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 24 ASIA-PACIFIC ENOXAPARIN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 25 ASIA-PACIFIC DALTEPARIN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 26 ASIA-PACIFIC OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 27 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION , 2017-2026 (USD MILLION)

TABLE 28 ASIA-PACIFIC ORAL IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 29 ASIA-PACIFIC INJECTABLES IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 30 ASIA-PACIFIC INJECTABLES IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 31 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 32 ASIA-PACIFIC CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 33 ASIA-PACIFIC CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 34 ASIA-PACIFIC ONCOLOGY IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 35 ASIA-PACIFIC RESPIRATORY IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 36 ASIA-PACIFIC NEPHROLOGY IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 37 ASIA-PACIFIC CNS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 38 ASIA-PACIFIC OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 39 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 40 ASIA-PACIFIC PRE-SURGICAL PROCEDURES IN ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 41 ASIA-PACIFIC POST-SURGICAL PROCEDURES IN ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 42 ASIA-PACIFIC KIDNEY DIALYSIS IN ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 43 ASIA-PACIFIC HEART VALVE REPLACEMENT IN ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 44 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 45 ASIA-PACIFIC GENERICS IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 46 ASIA-PACIFIC BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 47 ASIA-PACIFIC BRANDED IN ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 48 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 49 ASIA-PACIFIC HOSPITALS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 50 ASIA-PACIFIC CLINICS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 51 ASIA-PACIFIC HOMECARE IN ANTICOAGULATION THERAPY MARKET,BY REGION, 2017-2026 (USD MILLION)

TABLE 52 ASIA-PACIFIC AMBULATORY SURGICAL CENTERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 53 ASIA-PACIFIC OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 54 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 55 ASIA-PACIFIC HOSPITAL PHARMACY IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 56 RETAIL PHARMACIES IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 57 ASIA-PACIFIC ONLINE PHARMACIES IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 58 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY COUNTRY, 2017-2026 (USD MILLION)

TABLE 59 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 60 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 61 ASIA-PACIFIC NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 62 ASIA-PACIFIC HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 63 ASIA-PACIFIC VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 64 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 65 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 66 ASIA-PACIFIC INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 67 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 68 ASIA-PACIFIC CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 69 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 70 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 71 ASIA-PACIFIC BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION))

TABLE 72 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 73 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 74 JAPAN ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 75 JAPAN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 76 JAPAN NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 77 JAPAN HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 78 JAPAN VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 79 JAPAN ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 80 JAPAN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 81 JAPAN INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 82 JAPAN ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 83 JAPAN CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 84 JAPAN ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 85 JAPAN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 86 JAPAN BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 87 JAPAN ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 88 JAPAN ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 89 CHINA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 90 CHINA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 91 CHINA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 92 CHINA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 93 CHINA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 94 CHINA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 95 CHINA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 96 CHINA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 97 CHINA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 98 CHINA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 99 CHINA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 100 CHINA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 101 CHINA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 102 CHINA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 103 CHINA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 104 SOUTH KOREA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 105 SOUTH KOREA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 106 SOUTH KOREA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 107 SOUTH KOREA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 108 SOUTH KOREA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 109 SOUTH KOREA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 110 SOUTH KOREA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 111 SOUTH KOREA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 112 SOUTH KOREA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 113 SOUTH KOREA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 114 SOUTH KOREA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 115 SOUTH KOREA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 116 SOUTH KOREA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 117 SOUTH KOREA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 118 SOUTH KOREA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 119 INDIA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 120 INDIA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 121 INDIA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 122 INDIA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 123 INDIA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 124 INDIA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 125 INDIA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 126 INDIA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 127 INDIA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 128 INDIA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 129 INDIA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 130 INDIA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 131 INDIA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 132 INDIA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 133 INDIA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 134 AUSTRALIA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 135 AUSTRALIA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 136 AUSTRALIA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 137 AUSTRALIA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 138 AUSTRALIA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 139 AUSTRALIA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 140 AUSTRALIA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 141 AUSTRALIA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 142 AUSTRALIA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 143 AUSTRALIA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 144 AUSTRALIA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 145 AUSTRALIA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 146 AUSTRALIA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 147 AUSTRALIA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 148 AUSTRALIA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 149 SINGAPORE ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 150 SINGAPORE ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 151 SINGAPORE NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 152 SINGAPORE HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 153 SINGAPORE VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 154 SINGAPORE ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 155 SINGAPORE ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 156 SINGAPORE INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 157 SINGAPORE ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 158 SINGAPORE CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 159 SINGAPORE ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 160 SINGAPORE ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 161 SINGAPORE BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 162 SINGAPORE ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 163 SINGAPORE ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 164 THAILAND ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 165 THAILAND ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 166 THAILAND NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 167 THAILAND HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 168 THAILAND VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 169 THAILAND ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 170 THAILAND ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 171 THAILAND INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 172 THAILAND ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 173 THAILAND CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 174 THAILAND ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 175 THAILAND ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 176 THAILAND BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 177 THAILAND ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 178 THAILAND ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 179 MALAYSIA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 180 MALAYSIA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 181 MALAYSIA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 182 MALAYSIA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 183 MALAYSIA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 184 MALAYSIA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 185 MALAYSIA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 186 MALAYSIA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 187 MALAYSIA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 188 MALAYSIA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 189 MALAYSIA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 190 MALAYSIA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 191 MALAYSIA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 192 MALAYSIA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 193 MALAYSIA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 194 INDONESIA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 195 INDONESIA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 196 INDONESIA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 197 INDONESIA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 198 INDONESIA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 199 INDONESIA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 200 INDONESIA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 201 INDONESIA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 202 INDONESIA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 203 INDONESIA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 204 INDONESIA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 205 INDONESIA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 206 INDONESIA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 207 INDONESIA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 208 INDONESIA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 209 PHILIPPINES ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 210 PHILIPPINES ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 211 PHILIPPINES NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 212 PHILIPPINES HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 213 PHILIPPINES VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 214 PHILIPPINES ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 215 PHILIPPINES ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 216 PHILIPPINES INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 217 PHILIPPINES ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 218 PHILIPPINES CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 219 PHILIPPINES ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 220 PHILIPPINES ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 221 PHILIPPINES BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 222 PHILIPPINES ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 223 PHILIPPINES ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 224 REST OF ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions